Minimal residual disease (MRD) detection using quantification of clone-specific Ig or TCR rearrangements before and after transplantation in children with high-risk ALL is an important predictor of outcome. The method and guidelines for its interpretation are very precise to avoid both false-negative and -positive results. In a group of 21 patients following transplantation, we observed detectable MRD positivities in Ig/TCR-based real-time quantitative PCR (RQ-PCR) leading to no further progression of the disease (11 of 100 (11%) total samples). We hypothesized that these positivities were mostly the result of nonspecific amplification despite the application of strict internationally agreed-upon measures. We applied two non-self-specific Ig heavy chain assays and received a similar number of positivities (20 and 15%). Nonspecific products amplified in these RQ-PCR systems differed from specific products in length and sequence. Statistical analysis proved that there was an excellent correlation of this phenomenon with B-cell regeneration in BM as measured by flow cytometry and Ig light chain-j excision circle quantification. We conclude that although Ig/TCR quantification is a reliable method for post transplant MRD detection, isolated positivities in Ig-based RQ-PCR systems at the time of intense B-cell regeneration must be viewed with caution to avoid the wrong indication of treatment.
Introduction
During the past decade, minimal residual disease (MRD) monitoring using patient-specific antigen receptor gene rearrangements has been incorporated into major frontline and relapse treatment protocols for childhood ALL. [1] [2] [3] [4] Several groups, including ours, reported the unfavorable prognostic significance of high MRD levels before transplant in children with high-risk ALL. [5] [6] [7] [8] Studies exploring the significance of post transplant MRD were based on the detection of mixed chimerism, 9 ,10 flow cytometry (FC), 11 the fusion gene PCR in case of Ph þ ALL, 12 PCR using clone-specific Ig or TCR V-(D)-J sequences [13] [14] [15] [16] and, most recently, real-time quantitative PCR (RQ-PCR) detection of clonal Ig/TCR rearrangements. 17 Consistently, all studies showed that detectable MRD at any time after SCT represents a substantial risk of post transplant relapse, both in children and in adults. Several measures exist to avert hematological relapse after SCT when molecular relapse is detected. The first option is the reinforcement of the GVL effect by immunosuppression reduction or donor lymphocyte infusion (DLI); the second is the application of further cytoreductive therapy, including MoAb or specific tyrosine kinase inhibitors, in the case of BCR/ABL-positive ALL. [18] [19] [20] [21] [22] [23] [24] [25] [26] The benefit from such therapy has been described in a small proportion of ALL patients. To date, there is no general consent regarding the choice and timing of therapy in case of post transplant MRD positivity.
The ESG-MRD-ALL (European Study Group on Minimal Residual Disease in ALL) set guidelines for the interpretation of quantitative Ig/TCR-based MRD that include the use of polyclonal DNA from the peripheral blood (PB) of healthy donors in multiplicate as a negative control and a strict definition of MRD positivity. 27 This definition is even stricter when aimed at therapy intensification (for example, DLI) to prevent false-positive results. So far, this method has proved to be reliable, leaving the potential nonspecific amplification in regenerating nonmalignant lymphocytes only a theoretical possibility.
Starting 140 days and later after SCT, we observed MRD positivities in accordance with all ESG-MRD-ALL criteria in patients who subsequently turned MRD-negative without any antileukemic treatment and had been in complete remission for several years after SCT. We hypothesized that the B-cell regeneration after SCT caused an unspecific binding of clone-specific primers, which bypassed the otherwise strict ESG-MRD-ALL criteria for MRD positivity. MRD detection using non-self patient-specific assays revealed false MRD positivity in a substantial portion of post-SCT BM specimens. This false positivity was limited to the samples containing high numbers of B-cell progenitors as measured by immunophenotyping and by recently described B-cell recombination (k deleting) excision circles (KREC) detection. Moreover, using high-resolution capillary electrophoresis and sequencing, we observed that the size of such nonspecific RQ-PCR products differed from the specific products. We therefore conclude that MRD results post-SCT should be approached with extreme caution, and offer recommendations for avoiding MRD misinterpretation.
Patients and methods

Patients
A total of 38 children with ALL (aged 1-18 years) underwent allogeneic SCT in the Czech Republic from January 2003 to October 2006. Of them 21 patients with B-precursor ALL were selected for the study based on following criteria: leukemia-free survival with a follow-up of at least 12 months after transplant (median follow-up 46 months, range 17-62 months) and the availability of MRD results and residual DNA samples from at least three (3-7) of the following time points after SCT: days þ 30, þ 60, þ 100, þ 140, þ 180, 1 year, 2 years and 3 years. In total, 100 BM DNA samples (leftover material after MRD detection) were investigated. Washed leftover material from tubings and the transfusion bag following the complete administration of the BM graft was used as a control for KREC detection. Informed consent for the use of residual material after protocol-based examination for research purposes was obtained from patients or their guardians.
Transplants
The patients were transplanted due to relapsed or high-risk ALL in their first (7), second (11) or third (3) remission. Donors of hematopoietic stem cells were HLA-identical siblings in 5 cases, a sibling with 9/10 HLA antigen match in 1 case, and unrelated donors from BMT registries in 15 cases. BM was transplanted in ten cases, PBSC in nine cases, umbilical cord blood (UCB) in one case and both BM and UCB (sibling) in one case. In the majority of transplants (n ¼ 19), we used a similar pre-transplant conditioning regimen based on TBI at a dose of 12 Gy and etoposide 60 mg/kg, and in two children, a BU-based conditioning (1 Â BU, CY and melphalan, 1 Â BU, CY and etoposide) was used. In the majority of unrelated donor transplants (n ¼ 13), we used the rabbit antithymocytic globulin (Fresenius, Bad Homburg, Germany) at a dose of 10 mg/kg for 4 days. GVHD prophylaxis consisted of CsA in HLA-identical sibling transplants and a combination of CsA and MTX administered on days þ 1, þ 3 and þ 6 in unrelated donor transplants, respectively. In one patient (UCB transplant), a combination of CsA and methylprednisolone was used. No patient received any antileukemic treatment (including adoptive immunotherapy) during the post transplant period.
Detection of residual disease
Mononuclear cells from the diagnostic or relapse BM samples were isolated by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density centrifugation and stored in liquid nitrogen. Follow-up BM samples were processed by erythrocyte lysis and stored at À80 1C. Genomic DNA was isolated using a QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany). Primers and protocols for the detection of Ig heavy chain (IGH) rearrangements, Ig light chain-k deletions (KDE), TCR-g (TCRG), TCR-d (TCRD) gene rearrangements and TAL1 deletions have been described previously. 28, 29 Clonality of PCR products was confirmed by the heteroduplex analysis. 29 [30] [31] [32] [33] Ig/TCR RQ-PCR was performed in the iCycler IQ Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Standard curves were prepared by diluting the diagnostic samples in pooled polyclonal DNA from the PB of five healthy donors, which was also used as negative controls. MRD using patientspecific as well as non-self-specific systems was measured in triplicate, with 2.5 ml of DNA per reaction. The albumin gene was used to normalize the DNA concentration and quality. 34 The ESG-MRD-ALL criteria for RQ-PCR sensitivity, quantitative range and MRD interpretation were used. 27 DNA analysis by on-chip electrophoresis RQ-PCR product (1 ml) was analyzed in Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) using a DNA Series II Kit (DNA 1000 Assay) and Agilent 2100 Expert software according to the manufacturer's instructions.
Flow cytometry K3 EDTA BM aspirate specimens were stained within 12 h from sample collection using a whole-blood lysis technique with ammonium chloride. About 50-100 ml of sample (according to cellularity) was incubated with MoAb at dark for 15 min, and then sample was incubated with lysing solution for 15 min at dark and centrifuged (400 g). After supernatant removal, the sample was resuspended in 200 ml of PBS and analyzed on flow cytometer (FACSCalibur; BD Biosciences, San Jose, CA, USA or CyAn; Dako, Glostrup, 
Detection of B-cell receptor excision circles
We used the method of KREC detection, 36 slightly modified as follows. We did not employ the simultaneous detection of intron-Kde rearrangements as suggested. Instead, we used a DC t method with a calibrator sample-the donor DNA extracted from the residuum after BM transplantation. We considered the differences in DNA concentration of the samples and used RQ-PCR for the albumin gene as described previously. 34 The final amount of KREC relative to the calibrator was expressed as: 2 CtcalibratorÀCtsampleþlog2ðDNAconc:calibrator=DNAconc:sampleÞ :
Statistical analyses
The distribution of frequencies between groups with positive and negative MRD was assessed using Fisher's exact test. The Mann-Whitney test was used to estimate the significance of differences concerning continuous MRD values. The statistical analyses were performed using StatView version 5.0 (StatView Software, Cary, NC, USA). Trend analysis in Figure 4 was calculated using GraphPad Prism Software version 5 (GraphPad Software, San Diego, CA, USA). First, means of individual variables in individual time points were compared using one-way analysis of variance (ANOVA), then post-hoc linear trend analysis was used to test decrease or increase in naturally ordered groups. Simultaneously, Kruskal-Wallis test was used for comparison of means among individual time points.
Results
Frequency of hypothetically nonspecific amplification using patients' clone-specific systems in the course of prospective post-SCT monitoring A patient-specific RQ-PCR system with minimal sensitivity of 10 À4 was designed for all patients, and 17 out of 21 patients were monitored using two independent Ig/TCR targets. Figure 1 shows the results of post transplant MRD monitoring. In total, 16 of 151 (11%) samples from nine patients were MRD positive according to ESG-MRD-ALL criteria in at least one target (the C t value of at least one of the three replicates was within 4.0 from the highest C t value of the sensitivity and the C t value of at least one of the three replicates was X1.0 lower than the lowest C t of the background). 27 Eight samples fulfilled ESG-MRD-ALL criteria for positivity that aim at therapy intensification (the C t value of at least one of the three replicates was X3.0 lower than the lowest C t of the background). All samples were evaluated as 'positive, not quantifiable'. Fifteen of sixteen positive samples were examined by two targets; one sample was positive in both of them. The RQ-PCR targets with positive samples used IGH (7 Â ), KDE (5 Â ), TCRD (4 Â ) and TCRG (1 Â ) rearrangements for MRD detection. Nine of sixteen positive samples turned negative in the following BM examinations; three patients were still positive at the end of follow-up. Only 1 of 16 positive samples was taken during corticosteroid treatment of GVHD, compared to 51 of 135 negative samples (P ¼ 0.01).
On the basis of following, we hypothesized that most of the positive results were false positives and were most likely caused by unspecific binding of patient-specific primers to similar V-(D)-J sequences of nonmalignant lymphocytes in BM. First, all patients with at least one positive sample remained free of leukemia with a median follow-up of 31 months (range 17-61; not significantly different from patients with no positive sample, P ¼ 0.17, Mann-Whitney). Also, all patients who entered the study were MRD negative (n ¼ 16) or low positive (o5 Â 10
À4
, n ¼ 5) before the transplant. Finally, simultaneous RQ-RT-PCR detection of the respective fusion gene (BCR/ABL and TEL/ AML1) in 10 relevant samples tested gave a negative MRD result.
Frequency of amplification using non-self clone-specific systems Because of the suspicion of false positivity, we used different RQ-PCR systems specific for unique V-(D)-J sequences of two other patients (not specific for the leukemic cells of the given patients) to test whether the V-(D)-J sequences would even be amplified in such circumstances. A total of 100 post-SCT samples with sufficient leftover DNA were tested. The frequency of MRD-positive samples in the selected cohort did not differ from the whole cohort (11%).
We used two patient-specific systems based on the VH3-JH4 rearrangement. Both the VH3 family and JH4 represent the most frequently rearranged segments in physiological B-cell development. 37, 38 To maintain the reproducibility of the data, we used assays with no background amplification of polyclonal DNA from PB of healthy donors ('buffy coat' cells). The assays were originally designed for two patients with ALL (not included in the investigated cohort) using patient-specific primers situated with their 5 0 end in the VH3 segment and the last seven nucleotides spanning N segments. In total, 20 out of 100 (20%) and 15 out of 100 (15%) samples were positive according to the ESG-MRD-ALL criteria using those assays. Of the eleven samples positive in their own patientspecific systems, five and four were also positive in the two non-self clone-specific assays, respectively. Figure 2 shows C t values of false-positive samples in both assays. As the onset of positive signal was different between the two assays, their C t values are not mutually comparable. Given the fact that no background amplification was present, all samples would fulfill the criteria for therapy intensification.
27
Nonspecific RQ-PCR products differ from the specific products in length and sequence As we observed no difference in the length of most nonspecific RQ-PCR products on 8% polyacrylamide gel (data not shown), we employed a more sensitive Agilent DNA analysis by on-chip electrophoresis. Figure 3 shows an electrophoretogram of the diagnostic sample (1:10 000 dilution in buffy coat) of the patient whose assay was used for amplification compared to three different false-positive samples from different patients that differ in size and/or pattern.
Sequencing of 10 false-positive RQ-PCR products revealed the use of different N nucleotides downstream from the matching sequence of the patient-specific primer.
Assessment of B-cell reconstitution in the BM using KREC detection In the course of V-(D)-J recombination, Ig (TCR) gene segments are assembled, leaving nonreplicable circular DNA fragments as 'by-products'. T-cell recombination circles detection has been commonly used as a quantitative marker of thymic output. 39 Detection of B-cell recombination circles has not been widely employed due to the complicated structure of Ig genes. Recently, detection of excision circles originating in the deletions of Ig light chaink (KREC) was described. 36 As IGK deletion occurs in all B Positive samples: Figure 2 Ct values of false minimal residual disease (MRD) positive samples using two non-self-specific Ig/TCR assays. Filled and empty diamonds represent the two different assays. In the case that more members of the examined triplicate were positive, the highest C t value was used.
Drawbacks of post transplant MRD in childhood ALL E Fronkova et al lymphocytes that fail to rearrange IGK productively on one or both alleles, the number of KRECs in the BM reflects the number of developing B lymphocytes. Figure 4a shows the number of KRECs relative to the DNA from the BM donor sample during the post transplant period in 100 BM samples. With few exceptions, the KREC levels rose continuously, remaining lower than those of the control until day 90 and having a median value higher than the control 1-3 years post-SCT. This result was in concordance with the lower intensity of immunosuppression in later time points. Figure 5a shows the impact of immunosuppression taken at the time of sample collection on the number of KRECs for all time points together. Supplementary Figure 1 shows the same analysis for individual time points.
KREC number correlated well with the false positivities observed in non-self-specific Ig/TCR assays. Figure 6a shows the difference in the number of KRECs between the samples with negative and false-positive MRD. False MRD positivity was more frequent in samples with higher KREC number than in the negative ones (Po0.0001, MannWhitney). This trend was also significant for all but one (day 140) post-SCT time points tested individually (Supplementary Figure 2a) . 
Discussion
MRD monitoring using antigen receptor gene rearrangements offers a highly sensitive tool for post transplant management of high-risk ALL. On the basis of MRD positivity, methods of preemptive immunotherapy (DLI, immunosuppression withdrawal) or chemotherapy can be employed earlier than when using the less sensitive mixed chimerism or flow cytometric detection. However, our study demonstrated that even when all the criteria for MRD interpretation developed during the past decade are met, there is a considerable risk of false-positive MRD results after SCT. Even though all such results would be classified only as 'positive, not quantifiable', they would mean at best the necessity of repeated examination together with putting more stress on the patients and their parents, and at worst the application of preemptive treatment.
In our cohort, 9 of 21 patients were MRD-positive at least once during the first 3 years post-SCT using clonespecific Ig/TCR RQ-PCR assays. No patient has relapsed so far, with a median follow-up of 31 months. This number does not reflect the exact number of positive results in all transplanted patients, as our cohort was selected based on 
KREC relative to donor BM the leukemia-free survival and on the availability of post transplant material. Knechtli et al. 13 observed post transplant MRD positivity in 8 of 36 patients who remained in continuing complete remission. All MRDpositive samples in their study had been followed by negative ones, compared to 9 of 16 positive samples in this study. On the basis of the interim results, we already considered the last three positive samples in our study to be false positive and did not invite patients to undergo repeated examination out of schedule, so we have not received the MRD results so far. One can speculate that those positivities were real and reflected GVL effect preventing a hematological relapse. All of the patients selected for this study were MRD negative or low positive before the transplant, which has been shown to denote a low risk of post transplant relapse in several studies. [5] [6] [7] [8] 17 Moreover, 11 of 16 positive samples coming from patients with fusion genes were negative in simultaneous fusion transcript detection. We employed two non-self-specific RQ-PCR assays and observed a substantial percentage of false-positive amplifications in our cohort of samples. MRD monitoring based on antigen receptor gene rearrangements utilizes 'fingerprint-like' V-(D)-J sequences of leukemic clones for primer design. Nonspecific amplification in polyclonal lymphocytes with similar rearrangements is usually determined using pooled PB DNA from 5-10 healthy donors, and its occurrence depends on the type of Ig/TCR target and the number of inserted N nucleotides (about 30-40% in IGH whereas 90% in TCRG targets). 40 Recently, van der Velden et al. 41 reported that the level of nonspecific amplification in IGH targets depends on the time point during the induction treatment and is the highest in the post-maintenance period due to the prevalence of CD10 pos TdT neg precursor B cells with complete VH-JH rearrangements in the B-cell compartment. The authors concluded, however, that ESG-MRD-ALL guidelines for interpretation of RQ-PCR data were sufficient for frontline ALL therapy monitoring, with less than 2% false-positive results. As we were limited in sample size, so we could only analyze two IGH targets representing the same type (VH3 and JH4) of rearrangement to minimize assay-specific variations. Both assays had no background in PB buffy coat; still, we observed 20 and 15% false-positive results using regenerating post-SCT BM samples. Regarding immune cell reconstitution, SCT constitutes a unique situation. According to the KREC levels representing in our setting the output of B cells from BM, the median level remains lower than that of the control group until 1-year post-SCT. This result is in concordance with the study of Kook et al., 42 who observed a depression of total B-lymphocyte count until 18 months post-SCT. However, a fraction of patients had higher values than healthy BM donor starting in a few cases as soon as day 60 post-SCT, and creating more than half of the cohort 1-3 years post-SCT. Higher numbers of total B cells were also observed in a study of patients surviving 20-30 years after transplantation. 43 The problem of extensive regeneration causing unspecific primer binding could be theoretically overcome by using regenerating BM DNA instead of DNA from buffy coats as a negative control; however, the availability of such CsA, MP no IS n =44 n =18 P < 0.0001 Drawbacks of post transplant MRD in childhood ALL E Fronkova et al material in practice is very limited. Our recommendation is to continue using PB buffy coats while carefully judging cases of not quantifiable post-SCT MRD positivity. As all the RQ-PCR products we sequenced and analyzed by onchip electrophoresis differed from the specific ones, performing at least one of the two techniques would pay off in such cases.
The impact of preemptive therapy based on post transplant MRD or chimerism detection has not been proven so far on a larger cohort of patients. In our previous study, all attempts used to avert post-SCT relapse showed only a limited or temporary effect. 8 On the basis of these results, we are now working on pre-transplant MRD monitoring to enable adding treatment to minimize MRD level before the transplant and thus the risk of relapse. However, post transplant MRD monitoring still remains an extremely useful tool for therapy management, if judged with caution. 
